2025-07-20 - Analysis Report
Okay, here's a report analyzing Hims & Hers Health Inc. (HIMS), based on the data you provided.

**Report: Analysis of Hims & Hers Health Inc. (HIMS)**

**0. Executive Summary**

This report analyzes the performance of Hims & Hers Health Inc. (HIMS), a company focused on telehealth and personalized wellness, relative to the S&P 500 (VOO). The analysis includes a review of historical returns, technical indicators, recent news, earnings, and financial information to provide a comprehensive overview of the stock's current position and potential future performance.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** HIMS
*   **Company Description:** Hims & Hers Health Inc. is a telehealth company that provides personalized wellness and health solutions direct to consumers.
*   **HIMS Cumulative Return:** 179.43%
*   **VOO Cumulative Return:** 65.31%
*   **Absolute Divergence:** 114.1% (HIMS outperforms VOO)
*   **Relative Divergence:** 53.7% (Position within the historical divergence range)

**Analysis of Alpha and Beta**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------ | ----- | ------ |
| 2019-2021  | -46.0% | 51.0% | -84.0% | -0.0 | 1.5    |
| 2020-2022  | -15.0% | 72.1% | -17.0% | -0.0 | 1.4    |
| 2021-2023  | -51.0% | 72.1% | -69.0% | -0.1 | 2.0    |
| 2022-2024  | 127.0% | 78.4% | 101.0% | -0.1 | 5.4    |
| 2023-2025  | 174.0% | 78.4% | 126.0% | -0.1 | 11.3   |

*   **CAGR:** Varies significantly across periods, indicating volatile growth. Recent periods (2022-2025, 2023-2025) show very high growth.
*   **MDD:** High Maximum Drawdown values across all periods suggest substantial risk.
*   **Alpha:** Generally negative alpha indicates underperformance relative to the benchmark, except for the recent periods (2022-2025 and 2023-2025), where alpha is strongly positive, indicating significant outperformance.
*   **Beta:** Beta is near zero or negative, suggesting low correlation with the market.
*   **Cap(B):** Market capitalization has increased significantly, particularly in recent years.

**2. Recent Price Action**

*   **Last Price:** $50.38
*   **Previous Close:** $49.99
*   **Change:** 0.78%
*   **5-day Moving Average:** $50.94
*   **20-day Moving Average:** $49.04
*   **60-day Moving Average:** $50.50

The price is slightly above the 20-day moving average but below the 5-day and 60-day moving averages.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 52.44 (Neutral)
*   **PPO:** 0.49 (Positive Momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (4 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** -0.8 (Short-term decline)
*   **Expected Return:** -16.4% (Long-term underperformance vs. S&P 500)
*   **Volatile Issue:** The change in price of 0.78 indicates that the stock is experiencing recent volatility.

**4. Recent News & Significant Events**

*   **[2025-07-17]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-18]:** Analyst discussions about recent performance, industry trends, and global economic factors.
*   **[2025-07-20]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-19]:** Market experts highlight both risks and opportunities.

These news snippets suggest the stock is actively being influenced by both internal and external factors, leading to volatility.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
| ---------- | ---- | ----------- |
| 2025-05-05 | 0.22 | $0.59B      |
| 2024-11-04 | 0.35 | $0.40B      |
| 2024-08-05 | 0.06 | $0.32B      |
| 2024-05-06 | 0.05 | $0.28B      |
| 2025-05-05 | 0.05 | $0.28B      |

The earnings data shows increasing EPS and revenue figures over the observed period, indicating improving financial performance. The most recent data (2025-05-05) shows the highest EPS and revenue.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-03-31 | $0.59B    | 73.50%        |
| 2024-12-31 | $0.48B    | 76.81%        |
| 2024-09-30 | $0.40B    | 79.16%        |
| 2024-06-30 | $0.32B    | 81.30%        |
| 2024-03-31 | $0.28B    | 82.36%        |

Revenue has consistently increased over the quarters.  However, the profit margin has been decreasing.

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | ------- |
| 2025-03-31 | $0.55B    | 9.01%   |
| 2024-12-31 | $0.48B    | 5.46%   |
| 2024-09-30 | $0.44B    | 17.18%  |
| 2024-06-30 | $0.36B    | 3.67%   |
| 2024-03-31 | $0.34B    | 3.23%   |

Equity has increased, but ROE is volatile, with a peak in 2024-09-30 followed by a decline.

**7. Comprehensive Analysis**

Hims & Hers Health Inc. (HIMS) has shown substantial growth potential, as evidenced by its high cumulative return compared to the S&P 500. However, the significant volatility and negative alpha in earlier periods indicate a risky investment. The recent positive alpha suggests improving performance, but the high MDD highlights the potential for significant losses.

The increasing revenue and equity are positive signs, but the decreasing profit margin and volatile ROE raise concerns about the company's efficiency and profitability. The recent news indicates that the stock is influenced by market events and analyst opinions, contributing to volatility.

The technical indicators present a mixed picture, with a low-risk MRI but a negative expected return, suggesting potential underperformance in the long term.  The current price action and recent earnings reflect some positive momentum but warrant caution.

**In conclusion, HIMS presents a high-risk, high-reward investment opportunity. While the company has shown strong growth and improving financial performance, its volatility and potential for underperformance should be carefully considered.**
